Login to Your Account



FDA Panel Backs Allos, Gloucester Cancer Drugs

By Donna Young


Thursday, September 3, 2009
SILVER SPRING, Md. - FDA advisers Wednesday said the response rate and duration of response from Allos Therapeutics Inc.'s single-arm study were reasonably likely to predict the clinical benefit of Folotyn (pralatrexate) in treating patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription